Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Mond...
March 29 2018 - 8:30AM
Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s
biopharmaceutical company, announced that it has released financial
results for the full year ended December 31, 2017 and will host a
live conference call and webcast on Monday, April 2nd, 2018 at
4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to
discuss such results and to provide a general business
update.
The live webcast and a replay may be accessed by
visiting the investor relations section of Daré’s website at
http://www.darebioscience.com. Please connect to the Company's
website at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to
access the webcast.
Alternatively, please call (844) 831-3031 (U.S.)
or (443) 637-1284 (international) to listen to the live conference
call. The conference ID number for the live call is 7696698. Please
dial in approximately 10 minutes prior to the call.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s reproductive health that address
clear therapeutic gaps. The company is driven by a mission to
identify, develop and bring to market a diverse portfolio of novel
and differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health and
fertility. Daré currently has two product candidates in clinical
development. The first is Ovaprene™, a non-hormonal monthly
contraceptive ring intended to provide protection over multiple
weeks between menses. The second is SST-6007 (5% Topical Sildenafil
Citrate Cream), a potential treatment for Female Sexual Arousal
Disorder. SST-6007 incorporates sildenafil, the same active
ingredient in Viagra®, in a proprietary cream formulation that is
specifically designed to locally increase blood flow to the
vulvar-vaginal tissue in women, leading to a potential improvement
in genital arousal response and overall sexual experience. Daré
also has an option to enter into a license agreement for ORB-204
and ORB-214, preclinical stage injectable etonogestrel
contraceptives with target 6- and 12-month durations.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of The Private Securities Litigation
Reform Act of 1995 regarding matters that are not historical facts,
including statements relating to Daré's ability to develop Ovaprene
and Topical Sildenafil at the cost and in accordance with the
targeted timelines and milestones set forth herein, expectations
regarding the anticipated market demands for its products, the
safety and effectiveness of its products, market acceptance of
Daré's products and the qualifications and expertise of Daré's
management team. Because such statements are subject to risks
and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements as a
result of various important factors, including the uncertainties
inherent in the initiation and completion of clinical trials;
availability and timing of data from ongoing and future clinical
trials and the results of such trials; whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials will be
indicative of the results of later clinical trials, expectations
for regulatory approvals; claims of infringement and other risks
relating to Daré's owned and licensed intellectual property rights,
and other factors discussed in the "Risk Factors" section of Daré's
Report on Form 10-K filed with the Securities and Exchange
Commission on March 28, 2018. Additional information concerning
factors that could cause actual results to materially differ from
those in the forward-looking statements is contained in Daré's
reports to the Securities and Exchange Commission, including Daré's
reports on Forms 10-Q, 8-K and 10-K. In addition, any
forward-looking statements included in this press release represent
our views only as of the date of this release and should not be
relied upon as representing our views as of any subsequent date.
Daré specifically disclaims any obligation to update any
forward-looking statements included in this press release.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Ami
BavishiBurns McClellanabavishi@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda
GuisbondCanale Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024